tiprankstipranks
Trending News
More News >
Pluri (PLUR)
NASDAQ:PLUR

Pluri (PLUR) Price & Analysis

Compare
976 Followers

PLUR Stock Chart & Stats

$3.09
-$0.22(-4.74%)
At close: 4:00 PM EST
$3.09
-$0.22(-4.74%)

Pluri News

PLUR FAQ

What was Pluri’s price range in the past 12 months?
Pluri lowest stock price was $3.02 and its highest was $7.13 in the past 12 months.
    What is Pluri’s market cap?
    Pluri’s market cap is $30.35M.
      When is Pluri’s upcoming earnings report date?
      Pluri’s upcoming earnings report date is Feb 11, 2025 which is 305 days ago.
        How were Pluri’s earnings last quarter?
        Currently, no data Available
        Is Pluri overvalued?
        According to Wall Street analysts Pluri’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Pluri pay dividends?
          Pluri does not currently pay dividends.
          What is Pluri’s EPS estimate?
          Pluri’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Pluri have?
          Pluri has 9,253,897 shares outstanding.
            What happened to Pluri’s price movement after its last earnings report?
            Currently, no data Available
            Which hedge fund is a major shareholder of Pluri?
            Currently, no hedge funds are holding shares in PLUR

            Company Description

            Pluri

            Pluri (PLUR) is a biotechnology company focused on developing innovative therapies based on its proprietary technology platform for cell reprogramming and stem cell biology. Operating primarily in the healthcare and life sciences sectors, Pluri specializes in creating novel treatments for various diseases, particularly in regenerative medicine and immunotherapy. The company aims to harness the potential of pluripotent stem cells to address unmet medical needs and improve patient outcomes through advanced cellular therapies.
            Similar Stocks
            Company
            Price & Change
            Follow
            IGC Pharma
            Iterum Therapeutics
            PolyPid
            AN2 Therapeutics, Inc.
            Mural Oncology Plc

            Ownership Overview

            23.76%0.03%0.13%75.81%
            23.76% Insiders
            0.13% Other Institutional Investors
            75.81% Public Companies and
            Individual Investors

            Options Prices

            Currently, No data available
            ---
            Popular Stocks